The Science
NEED SOME CONTENT HERE
Current treatments are either ineffective, too expensive or present severe side effects.
BioTheraMin
natural extract cannabinoid API for acute therapy migraine pain relief
R & D
Pre-Clinical
Phase 1
Phase 2/3
Approval
- BioTheraMin™ Acute Migraine
Properly Dosed | Consistent | Uniform
Natural extract Cannabinoid-based acute migraine therapeutic
Cannabinoid Studies between 2020-2022 over 3000 patients
%
Immediate symptom relief
%
Reduction in migraine severity
%
More effective than non-cannabis products
BioTheraCin
natural extract psilocybin API for preventative therapy for cluster headache management
R & D
Pre-Clinical
Phase 1
Phase 2/3
Approval
- BioTheraCinCH™ Preventative Cluster Headache
BioTheraCin
Properly Dosed | Consistent | Uniform
Natural extract Cannabinoid-based acute migraine therapeutic
48 cluster headache patients who used psilocybin
%
Abortion of the cluster attack
%
Cluster period termination
%
Remission period extension
BioTheraCin
natural extract psilocybin API for preventative therapy for reduction of migraine days
R & D
Pre-Clinical
Phase 1
Phase 2/3
Approval
- BioTheraCinMH™ Preventative Migraine
This exploratory study suggests there is an enduring therapeutic effect in migraine headache after a single administration of psilocybin
Contact Us
Headquarter
1200, 1015 4th Street SW
Calgary AB, Canada
Phone
+1 (403) 880-7598
Info@bluetherabio.com
Facility
239 Aqaduck Drive E,
Brooks AB, Canada